bluuebunny/crossref_metadata_2025_split huggingface dataset:
Evaluation of endocrine therapy combined with intensity modulated radiation therapy in patients with advanced prostate cancer
Authors: Ma Xiulong , Ma Hongbing , Ruan Dongli 
Published: June 2023

Abstract

Objective
The aim of this study was to study the effect of endocrine therapy combined with intensity-modulated radiation therapy in patients with advanced prostate cancer.

Methods
The clinical data of 231 patients with advanced prostate cancer treated with radiotherapy in our hospital from May 2010 to March 2018 were collected. A total of 135 patients were treated with endocrine therapy combined with intensity-modulated radiotherapy, and 96 patients were treated with intensity-modulated radiotherapy only because of drug allergy, serious adverse reactions, and economic reasons. Two months after the end of the treatment, the short-term curative effect was evaluated using imaging reexamination. The total prostate-specific antigen (TPSA) and free prostate-specific antigen (FPSA) were detected before and 2 months after the end of the treatment. All patients were followed up for at least 3 years, and the metastasis-free survival rate and cumulative survival rate of the two groups were calculated.

Results
The remission rates (RRs) of the observation and control groups were 64.45% and 46.87%, respectively; the difference was not statistically significant (P > 0.05); however, the efficacy distribution of the endocrine therapy combined with intensity-modulated radiotherapy group was significantly better than that of the intensity-modulated radiotherapy group (P < 0.05). There was no significant difference in clinical efficacy between the two groups in different TNM stages and Gleason grades. After treatment, the levels of TPSA and FPSA were significantly decreased compared with those before treatment; however, the decrease in the endocrine therapy combined with the intensity-modulated radiation therapy (IMRT) group was significantly higher than that in the IMRT group (P < 0.05). Although there were no significant differences in the 1-year and 3-year cumulative survival rates between the two groups, the 1-year and 3-year metastasis-free survival rates of the endocrine therapy combined with the IMRT group were 60% and 38.17%, respectively, which were significantly higher than those of the IMRT group (37.5% and 20.83%, P < 0.05).

Conclusion
Endocrine therapy combined with IMRT significantly improved the clinical efficacy of advanced prostate cancer, reduced PSA (prostate specific antigen) levels, and improved the metastasis-free survival rates.
Malnutrition as a predictor of prolonged length of hospital stay in patients with gynecologic malignancy: A comparative analysis*
Authors: Chen Yongning , Li Runrong , Zheng Li , Liu Wenlian , Zhang Yadi , Gong Shipeng 
Published: June 2023

Abstract

Objective
To explore the consistency of the Patient-generated Subjective Global Assessment (PG-SGA) and Nutritional Risk Screening-2002 (NRS-2002) for nutritional evaluation of patients with gynecologic malignancy and their predictive effect on the length of hospital stay (LOS).

Methods
We recruited 147 hospitalized patients with gynecologic malignancy from Nanfang Hospital in 2017. Their nutritional status was assessed using the PG-SGA and NRS-2002. The consistency between the two assessments was compared via the Kappa test. The relationship between malnutrition and LOS was analyzed using crosstabs and Spearman’s correlation.

Results
The PG-SGA demonstrated that 66.7% and 54.4% of patients scoring ≥ 2 and ≥ 4 were malnourished, respectively. Furthermore, the NRS-2002 indicated that 55.8% of patients were at nutritional risk. Patients with ovarian cancer had a relatively high incidence of malnutrition. However, this was only significant for patients who scored ≥ 4 in the PG-SGA (P = 0.001 and P = 0.019 for endometrial carcinoma and cervical cancer, respectively). The PG-SGA and NRS-2002 showed good consistency in evaluating the nutritional status of patients with gynecologic malignancy (0.689, 0.643 for PG-SGA score ≥ 2, score ≥ 4 and NRS-2002, respectively). Both the scores of PG-SGA and NRS-2002 were positively correlated with LOS. Furthermore, prolonged LOS was higher in patients with malnutrition than in those with adequate nutrition.

Conclusion
The PG-SGA and NRS-2002 shared a good consistency in evaluating the nutritional status of patients with gynecologic malignancy. Both assessments could be used as predictors of LOS.
Correlation analysis of breast fibroadenoma and the intestinal flora based on 16S rRNA sequencing*
Authors: Wang Bingdong , Liu Xin , Bian Yahong , Sun Guoxin , Wang Huizhe , Zhang Jingjin , Zhang Zhengfu , Zou Xiao 
Published: June 2023

Abstract

Objective
To analyze the characteristics of the intestinal microflora in patients with breast fibroadenoma using 16S ribosomal RNA (rRNA) high-throughput sequencing.

Methods
Fecal samples from 20 patients with breast fibroadenoma and 36 healthy subjects were randomly collected and analyzed using high-throughput sequencing technology for 16S rRNA V4 region sequencing, and the alpha diversity (Chao index, Shannon index) was calculated using Mothur (v.1.39.5) software. Beta diversity was analyzed using QIIME (v1.80). SPSS software (version 23.0) and the t-test of two independent samples were used to analyze differences in the abundance of bacteria between the two groups.

Results
Compared with that in the healthy control group, the α diversity of the intestinal microflora in breast fibroadenoma patients increased, but the difference was not statistically significant (P > 0.05). At the phylum level, significant differences were observed between the two groups. The abundance of Firmicutes was higher in the breast fibroadenoma group (P < 0.05), whereas the abundance of Synergistetes was higher in the healthy control group (P < 0.005). A total of five bacterial genera showed significant differences between the two groups: the breast fibroadenoma group showed higher levels of Bautia (P < 0.005), Coprococcus (P < 0.005), Roseburia (P < 0.05), and Ruminococcus (P < 0.005), whereas Sutterella was more abundant in the healthy control group than in the breast fibroadenoma group (P < 0.05).

Conclusion
The diversity and abundance of the intestinal flora in patients with breast fibroadenoma are significantly different from those in healthy subjects, suggesting that an imbalance in the intestinal flora is correlated with the occurrence of breast fibroadenoma.
SMARCC1 copy number variation is related to metastatic colon cancer: an investigation based on TCGA data*
Authors: Feng Libo , Liu Yu , Xia Dong , Chen Xiaolong 
Published: June 2023

Abstract

Objective
There are no well-defined genetic indicators for distant metastatic illness in patients with colon cancer (CC). The discovery of genetic changes linked to metastatic CC might aid in the development of systemic and local therapeutic approaches. Using The Cancer Genome Atlas (TCGA), we examined the relationship between copy number variation (CNV) of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 1 (SMARCC1) and distant metastatic illness in patients with CC.

Methods
Genetic sequencing data of all relevant CC patients and clinical features were collected from TCGA using R. There were 506 CC patients with CNV and clinical outcome data. The CNV of SMARCC1 was examined for its correlation with distant metastatic disease using the TCGA CC dataset (M1 vs. M0). After adjusting for age, sex, T stage, N stage, adjuvant chemotherapy, microsatellite instability (MSI), and surgical margin status, univariate and multivariate logistic regression analyses were performed.

Results

SMARCC1 CNV was linked to distant metastatic disease (P = 0.012 and 0.008 in univariate and multivariate analysis, respectively); positive lymph nodes and margin status were also associated with distal metastases (all P < 0.01). MSI, T stage, N stage, adjuvant treatment, sex, race, and MSI were not associated with metastases (all P > 0.05).

Conclusion

SMARCC1 CNV is associated with distant metastatic disease in patients with CC. In individuals with CC, such genetic profiles might be utilized therapeutically to support optimal systemic treatment options against local treatments for CC, such as radiation therapy, pending additional confirmation.
Risk factors for lymph node metastasis of cN0 papillary thyroid carcinoma
Authors: Niu Guangcai , Guo Hao 
Published: June 2023

Abstract

Objective
To investigate the risk factors for cervical lymph node metastasis of clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC).

Methods
Patients and Methods: The clinicopathologic data of patients with cN0 PTC who underwent at least one lobectomy plus central lymph node dissection at Xuzhou Central Hospital from January 2018 to December 2020 were retrospectively collected and the risk factors of lymph node metastasis analyzed. Univariate and multivariate analyses were performed to detect the risk factors for cervical lymph node metastasis.

Results
A total of 312 patients with cN0 PTC were enrolled in this study. The postoperative pathology results showed that 134 patients (42.9%) had central lymph node metastasis, of whom 24 (17.9%) had lateral lymph node metastasis (LLNM). The univariate analysis results showed that male gender, age <45 years, tumor diameter ≥10 mm, bilateral cancer, capsule invasion, and multiple foci were associated with cervical lymph node metastasis of cN0 PTC (P < 0.05). Further logistic regression analysis results showed that these factors, except age, were independent risk factors for cervical lymph node metastasis of cN0 PTC (P < 0.05). The results also showed that the risk of LLNM increased with an increase in the number of positive central lymph nodes in patients with cN0 PTC (P < 0.05).

Conclusion
Cervical lymph node metastasis of cN0 PTC is related to many factors, and a high number of positive central lymph nodes indicates a high risk of LLNM. Patients with risk factors should undergo preventive central lymph node dissection at the first surgery, and in patients with a high number of positive central lymph nodes, lateral lymph node dissection should be discreetly performed.
Case report of a mixed pulmonary large cell neuroendocrine carcinoma
Authors: Quan Xiaoying , Chen Xiaoyan , Lei Lei , Jia Xiaoli , Wu Chunzhi , Ye Bin 
Published: June 2023

Abstract
A 57 year-old male patient was found to have a lesion in the middle lobe of his right lung using chest computed tomography (CT). Tumor cells were detected, and surgical excision was performed. The patient was diagnosed with mixed large cell neuroendocrine carcinoma, and underwent six cycles of a chemotherapy regimen comprising etoposide combined with cisplatin. Genetic testing revealed an EGFR mutation, which prompted oxitinib-targeted therapy. To date, no signs of recurrence or metastasis have been reported.
Immunotherapy induced hypothyroidism with hyperlipidemia: a case report and literature review
Authors: Yang Yang , He Lilin 
Published: June 2023

Abstract
In recent years, immune checkpoint inhibitors have been increasingly used in clinical practice. While considering the efficacy of immunotherapy, it is also necessary to be alert to immune-related adverse effects (irAEs). These include skin, gastrointestinal, liver, endocrine, and pulmonary toxicities. Here, we report a case of irAEs of hypothyroidism with marked hyperlipidemia during sintilimab administration.
One-stage limb Pelnac® reconstruction after removal of skin cancer: safety, efficacy, and aesthetic outcomes
Authors: Shi Jia , Gao Min , Zhu Haijun , Lu Weiwei 
Published: June 2023

Abstract

Objective
To assesse the outcomes of one-stage limb reconstruction after removal of skin cancers defect.

Methods
This prospective study was conducted from September 2017 to January 2020 and included 15 patients. All patients underwent extensive tumor resection and one-stage Pelnac® reconstruction of large skin defects, and regular postoperative follow-up was scheduled. At the 6-month follow-up, tumor recurrence and scar quality was assessed using the Vancouver Scar Scale (VSS). None of the patients exhibited infection, wound necrosis, hematoma, seroma, or recurrence.

Results
All the skin grafts were well accepted by the patients. Nine patients reported normal or near-normal sensory function, while six reported slight sensory loss. No cases of significant functional loss were observed. We enrolled 10 men and 5 women with a mean age of 63.9 years (range: 46-78 years). The mean follow-up duration was 20.6 months (range: 12-36 months). The skin tumors were located on the feet (n = 4), forearms (n = 3), and legs (n = 8). The malignant tumors included malignant melanomas (13.3%), basal cell carcinomas (33.3%), and squamous cell carcinomas (53.3%). The mean operative time was 40.7 min. Two patients underwent radiotherapy. The average length of hospital stay was 2.6 days. The mean skin defect area was 33.2 cm2 (range: 16.6-51.6 cm2). The patient satisfaction score (regarding the aesthetic appearance of the grafted area) was 79.7/100, and the VSS score was 3.8.

Conclusion
Pelnac® dermal templates facilitate efficient and reliable reconstruction of skin defects after skin cancer resection.
Prognostic value of the long noncoding RNA AFAP1-AS1 in cancers*
Authors: Zhu Lixiu , Yan Jiawen , Xu Guoqiang , Wang Qiaoli , Xu Tianrui , Cao Ruixue , Sun Chuanzheng , Xi Yan , Xiong Wei 
Published: June 2023

Abstract

Objective
This meta-analysis explored whether the expression of actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is related to the prognosis and clinicopathological features of patients with cancer.

Methods
PubMed, EMBASE, and Cochrane Library were systematically searched. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the prognostic value based on overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Odds ratios (ORs) with 95% CIs were used to determine the relationships between AFAP1-AS1 and clinicopathological features, such as large tumor size (LTS), high tumor stage (HTS), poor histological grade (PHG), lymph node metastasis (LNM), and distant metastasis (DM).

Results
Thirty-five eligible articles and 3433 cases were analyzed. High AFAP1-AS1 expression, compared to low AFAP1-AS1 expression, correlated with significantly shorter OS (HR = 2.15, 95% CI = 1.97-2.34, P < 0.001), DFS (HR = 1.37, 95% CI = 1.19-1.57, P < 0.001), and PFS (HR = 1.97, 95% CI = 1.56-2.50, P < 0.001) in patients with cancer. In various cancers, elevated AFAP1-AS1 expression was significantly associated with LTS (OR = 2.76, 95% CI = 2.16-3.53, P < 0.001), HTS (OR = 2.23, 95% CI = 1.83-2.71, P < 0.001), and PHG (OR = 1.39, 95% CI = 1.08-1.79, P = 0.01) but not LNM (OR = 1.59, 95% CI = 0.88-2.85, P = 0.12) or DM (OR = 1.81, 95% CI = 0.90-3.66, P = 0.10).

Conclusion
High AFAP1-AS1 expression was associated with prognostic and clinicopathological features, suggesting that AFAP1-AS1 is a prognostic biomarker for human cancers.
EZH2 is a biomarker associated with lung cancer diagnosis and immune infiltrates without prognostic specificity: a study based on the cancer genome atlas data*
Authors: Wang Xiaokun , Qi Min , Zhu Xu , Zhao Zhengtong , Cao Yufeng , Xing Daijun , Wang Fuman , Lin Gaoyang 
Published: June 2023

Abstract
Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive complex 2 (PRC2). Dysregulation of EZH2 causes alteration of gene expression and functions, thereby promoting cancer development. Recent studies suggest that EZH2 has a potential prognostic role in patients with non-small cell lung cancer (NSCLC). However, the prognostic value of EZH2 expression levels in NSCLC is controversial. In this study, we evaluated the prognostic value in lung cancer (LC-LUAD/LUSC) based on data from The Cancer Genome Atlas (TCGA) database. Kruskal-Wallis test, Wilcoxon signed-rank test, and logistic regression were used to evaluate the relationship between EZH2 expression and clinicopathological features. Cox regression and the Kaplan-Meier method were adopted to evaluate prognosis-related factors. Gene set enrichment analysis (GSEA) was performed to identify the key pathways related to EZH2. The correlations between EZH2 and cancer immune infiltrates were investigated by single-sample Gene Set Enrichment Analysis (ssGSEA). EZH2 was found to be up regulated with amplification in tumor tissues in multiple LC cohorts. High EZH2 expression was associated with poorer overall survival (OS). GSEA suggested that EZH2 regulates innate immune system, ECM affiliated, matrisome, surfactant metabolism. Notably, ssGSEA indicated that EZH2 expression was positively correlated with infiltrating levels of Th2 cells and significantly negatively correlated with mast cell infiltration level. These results suggest that EZH2 is associated with LC immune infiltration and significantly over-expressed in lung cancer, and its diagnostic value is better than prognosis, which lays a foundation for further study of the immunomodulatory role of EZH2 in LC.
Xiaoaiping injection affects the invasion and metastasis of hepatocellular carcinoma by controlling AFP expression
Authors: Huang Shu , Wang Ganxin 
Published: June 2023

Abstract

Objective
Xiaoaiping (XAP) is a traditional Chinese medicine that is a commonly used as an anticancer drug in clinical practice owing to its high efficiency and low toxicity. Specifically, XAP can effectively inhibit the growth of hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is a key HCC diagnostic marker and is closely related to certain malignant cytological behaviors of HCC. However, whether AFP expression and XAP treatment are related to the invasion and metastasis of HCC remains unclear. In the present study, we aimed to evaluate the effects and underlying mechanism of XAP on the invasion and metastasis of HCC..

Methods
Using a cell scratch assay, Transwell technology, and western blotting we detected the different invasion and metastatic abilities of Hep3B cells in XAP treatment and blank control groups. This allowed comparison of the invasion and metastatic abilities of Hep3B cells with differing levels of AFP expression. AFP mRNA sequencing technology was used to analyze the mechanism of tumor invasion and metastasis associated with AFP and XAP treatment.

Results
Cell invasion and metastasis abilities in the XAP group were significantly lower than those in the control group (P < 0.05). Additionally, compared to the control group, the expression of AFP significantly decreased after XAP treatment (P < 0.05). The ability of Hep3B cells to invade and metastasize was promoted when AFP expression was up-regulated, whereas it was inhibited when AFP was silenced. XAP injection and AFP regulate the invasion and metastatic ability of HCC by affecting matrix metalloproteinases (MMPs).

Conclusion
XAP injection inhibits the invasion and metastatic ability of HCC by influencing the expression of AFP; additionally, this inhibition of AFP is achieved by affecting MMPs.
AGAP2-AS1 affects TNM staging and prognosis of lung cancer patients by acting on SLC7A11 mRNA stability and ferroptosis*
Authors: Huang Lin , Li Bin , Hu Zuowei 
Published: June 2023

Abstract

Objective
The initiation and progression of lung carcinomas are critically regulated by long non-coding RNAs (lncRNAs). However, the role of lncRNAs in the pathways causing lung cancer remains unknown.

Methods
Cell morphology was regularly observed using an inverted phase-contrast microscope. Cell viability was assessed using CCK-8 according to the manufacturer’s instructions. Total RNA was retrotranscribed from each specimen using the RNAiso Plus Kit. The RT-PCR data were calculated using the Ct approach for comparison. Flow cytometric analyses were prepared by Click-iT™ Plus TUNEL Assay for In Situ apoptosis detection, with Alexa Fluor™ 594 dye, as instructed. RNA immunoprecipitation assays were used to determine RNA concentration.

Results
Activated natural killer cells repeat and PH domain-containing protein 2 antisense RNA 1 (AGAP2-AS1) levels in cancerous tissues were significantly correlated with cancerous tumor node metastasis (TNM) stage, with cancerous AGAP2-AS1 levels being higher in cancerous tissues than healthy tissues. Patients withelevated AGAP2-AS1 levels had considerably worse outcomes than those with reduced AGAP2-AS1 levels, regardless of the progression-free or overall survival. Functionally, AGAP2-AS1 downregulation represseslung cancer cell growth. AGAP2-AS1 elimination induces erastin-mediated ferroptosis in lung cancer cells.However, the ferritin inhibitor FERSINT-1 negated this result, whereas ERASTIN induced lung cancer cellmortality. After AGAP2-AS1 silencing, erastin-treated lung cancer cells showed a remarkable decrease inGSH levels. These results indicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via Recombinant Insulin Like Growth Factor Binding Protein 2(IGF BP2). Patients with elevated AGAP2-AS1 had considerably worse outcomes. Down-regulating AGAP2-AS1 was able to repress lung cancer cell growth and induce greater Erastin-mediated ferroptosis. Lungcancer cells treated with Erastin exhibited a remarkable decrease inglutathione (GSH) levels. The mechanical findingsindicated that AGAP2-AS1 enhanced the stabilization of SLC7A11 mRNA via the IGF2BP2.

Conclusion
We identified a novel effect of AGAP2-AS1 on TNM staging and the prognosis of patientswith lungcancer by modulating SLC7A11 mRNA stability and ferroptosis.
Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury
Authors: Yuan Xianglin 
Published: June 2023

Abstract
Thrombocytopenia and liver injury are serious clinical problems in patients with cancer. The etiology of thrombocytopenia in patients with cancer and liver injury (TCLI) is complicated. Managing cancer therapy-induced thrombocytopenia has gradually become standardized, and managing liver injury-associated thrombocytopenia has become more effective with the approval and marketing of relevant drugs. However, the optimal strategy for managing thrombocytopenia in patients with cancer and liver injury remains unclear, and the superposition of thrombocytopenia and liver injury further increases the difficulty of cancer treatment. Therefore, the Committee of Cancer Support Therapy of the Chinese Anti-Cancer Association has organized experts to analyze and discuss relevant literature to form a Chinese expert consensus on managing thrombocytopenia in patients with cancer and liver injury (2022 Edition) to guide clinical practice.
Research progress on immunotherapy targeting the tumor immune microenvironment for cholangiocarcinoma*
Authors: Ma Tianyin , Chen Zhang , Chai Yibo , Gongye Xiangdong , Xia Peng , Qu Chenming , Tian Ming , Yuan Yufeng 
Published: June 2023

Abstract
Cholangiocarcinoma (CCA) is the second most common hepatobiliary cancer, and its incidence has increased significantly in recent years. CCA has poor prognosis owing to the limited diagnosis and treatment options. The tumor immune microenvironment (TIME), which comprises immune cells, cytokines, and chemokines, plays a significant role in cancer progression, the evasion of immune surveillance, and therapeutic responses. Immunotherapeutic strategies targeting the TIME offer the potential for the recognition and eradication of CCA. This review discusses the cellular and molecular components of the TIME in CCA and immunotherapeutic strategies targeting it.